MedKoo Cat#: 573849 | Name: Migalastat free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Migalastat, also known as AT1001 or GR181413A, is a pharmacological chaperone. Migalastat binds selectively and reversibly to the active site of alpha-galactosidase A (α-Gal A), stabilizing the mutant enzyme and facilitating its proper trafficking to lysosomes, where it can degrade accumulated globotriaosylceramide (GL-3). In vitro, migalastat has shown increased α-Gal A activity in patient-derived fibroblasts with amenable mutations—often yielding ≥1.2-fold enhancement in enzymatic activity relative to baseline.

Chemical Structure

Migalastat free base
Migalastat free base
CAS#108147-54-2 (free base)

Theoretical Analysis

MedKoo Cat#: 573849

Name: Migalastat free base

CAS#: 108147-54-2 (free base)

Chemical Formula: C6H13NO4

Exact Mass: 163.0845

Molecular Weight: 163.17

Elemental Analysis: C, 44.17; H, 8.03; N, 8.58; O, 39.22

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Amigal, DDIG, Migalastat; 1-Deoxygalactonojirimycin; 1-Deoxygalactostatin; AT1001; AT 1001; AT-1001; GR181413A; GR 181413A; GR-181413A; Galafold
IUPAC/Chemical Name
(2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
InChi Key
LXBIFEVIBLOUGU-DPYQTVNSSA-N
InChi Code
1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1
SMILES Code
[C@@H]1([C@H]([C@H](NC[C@@H]1O)CO)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Migalastat (GR181413A free base) is an orally active and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM.
In vitro activity:
TBD
In vivo activity:
Western blots of the proteins indicated that there was an increase in stability of WT α-Gal A in flies treated with 50 μM migalastat (Figure 2A,B). There was a 2.5- and a 3-fold increase in the total amount of the A156V α-Gal A following 10 μM and 50 μM chaperone treatment, respectively, and elevation in the lysosomal fraction of the mutant protein, indicating that migalastat is able to bind the protein and to assist in its folding and trafficking from the ER to the lysosomes (Figure 2C,D). Moreover, even in the A285D-expressing flies, there was a 2.5-fold increase in the total amount of α-Gal A, as well as appearance of a small lysosomal fraction, following 20 μM migalastat treatment (Figure 2E,F). Reference: Int J Mol Sci. 2020 Oct; 21(19): 7397. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583893/

Preparing Stock Solutions

The following data is based on the product molecular weight 163.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Braunstein H, Papazian M, Maor G, Lukas J, Rolfs A, Horowitz M. Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat. Int J Mol Sci. 2020 Oct 7;21(19):7397. doi: 10.3390/ijms21197397. PMID: 33036426; PMCID: PMC7583893.
In vitro protocol:
TBD
In vivo protocol:
1. Braunstein H, Papazian M, Maor G, Lukas J, Rolfs A, Horowitz M. Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat. Int J Mol Sci. 2020 Oct 7;21(19):7397. doi: 10.3390/ijms21197397. PMID: 33036426; PMCID: PMC7583893.
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548736/ PubMed PMID: 31644045. 2: McCafferty EH, Scott LJ. Migalastat: A Review in Fabry Disease. Drugs. 2019 Apr;79(5):543-554. doi: 10.1007/s40265-019-01090-4. Review. Erratum in: Drugs. 2019 Jul 10;:. PubMed PMID: 30875019; PubMed Central PMCID: PMC6647464. 3: Migalastat for Fabry disease. Aust Prescr. 2019 Feb;42(1):36-37. doi: 10.18773/austprescr.2018.073. Epub 2018 Dec 13. Review. PubMed PMID: 30765910; PubMed Central PMCID: PMC6370600. 4: Pharmacoeconomic Review Report: Migalastat (Galafold): (Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533451/ PubMed PMID: 30457791. 5: CADTH Canadian Drug Expert Committee Recommendation: Migalastat (Galafold — Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533471/ PubMed PMID: 30457790. 6: Clinical Review Report: Migalastat (Galafold): (Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533676/ PubMed PMID: 30457788. 7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK532501/ PubMed PMID: 30372005.